// App-Quantinova.ai

DOP20 : Drugs that modulate histone acetylation disrupt TGF-β-signalling and reduce collagen I expression in models of stricturing Crohn’s disease

Researchers

Presenter

  • A Lewis

Principal Investigators

  • A Nijhuis

  • G Berti

  • C Felice

  • R Jeffrey

  • S Iqbal

  • A B Pomeranc

  • S Aldelemi

  • S Mehta

  • E Giannoulatou

  • R Feakins

  • A Armuzzi

  • J O Lindsay

  • A Silver

Medical Centers

  • Blizard Institute, Barts and The London School of Medicine and Dentistry, Centre for Genomics and Child Health, London, UK

  • IBD Unit, Presidio Columbus Fondazione Policlinico Universitario A. Gemelli IRCCS - Università Cattolica del Sacro Cuore, Rome, Italy

  • Victor Chang Cardiac Research Institute and 4St Vincent’s Clinical School, University of New South Wales, Sydney, Australia

  • Department of Histopathology, The Royal London Hospital, London, UK

  • Blizard Institute, Barts and The London School of Medicine and Dentistry, Centre for Immunobiology, London, UK

Locations

  • United Kingdom

  • Italy

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • Crohn's disease

Biomarkers

  • Stearoyl-CoA desaturase

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved